Disc Medicine, Inc. has filed a Form 144 to report a proposed sale of securities, a move that may indicate liquidity strategies by insiders. This filing, dated October 21, 2026, is significant as it highlights potential shifts in ownership and financial strategies within the company.
Background
Disc Medicine, Inc. operates in the pharmaceutical preparations sector, classified under SIC code 2834. The company is publicly traded on the Nasdaq under the ticker symbol IRON. As a large accelerated filer, Disc Medicine has been actively engaging with investors through various filings, indicating a proactive approach to its financial management.
What the Filing Says
Details were not available in the SEC filing. However, the Form 144 is typically used to report the proposed sale of securities by insiders, which may suggest that the company’s executives or major shareholders are looking to liquidate some of their holdings.
Impact
This filing may affect current and potential investors, as insider sales can often influence market perception and investor sentiment. Additionally, competitors in the pharmaceutical preparations industry will likely monitor this move closely, as it could indicate broader trends in the sector.
What's Next
The filing does not say what happens next.
Filer Information
The filing indicates that the proposed sale of securities is reported by Atlas Venture Fund XII, L.P., which is classified under the Central Index Key (CIK) number 0001812049. This entity is based in Delaware and has a fiscal year ending on December 31.
Company Details
Disc Medicine, Inc. is also identified with its own Central Index Key (CIK) number 0001816736, and it operates within the pharmaceutical preparations industry under the SIC code 2834. The company has a fiscal year that also ends on December 31.
Mailing and Business Addresses
Both the mailing and business addresses for Disc Medicine, Inc. are listed as 400 Technology Square, 10th Floor, Cambridge, MA 02139, with a contact number of 857-201-2700. This location may serve as a hub for its operational activities.
Document Availability
The filing includes two documents: a primary document in both HTML and XML formats, and an exhibit (EX-99) in PDF format. The primary document is crucial for understanding the specifics of the proposed sale, while the exhibit may contain additional relevant information regarding the transaction.
Absence of Specific Sale Details
While the Form 144 provides a framework for reporting proposed sales, it does not disclose the exact number of shares to be sold or the intended use of proceeds from the sale. Such details are often critical for investors assessing the implications of insider transactions.